[go: up one dir, main page]

EA200600648A1 - Производные пурина, ингибирующие репликацию вич - Google Patents

Производные пурина, ингибирующие репликацию вич

Info

Publication number
EA200600648A1
EA200600648A1 EA200600648A EA200600648A EA200600648A1 EA 200600648 A1 EA200600648 A1 EA 200600648A1 EA 200600648 A EA200600648 A EA 200600648A EA 200600648 A EA200600648 A EA 200600648A EA 200600648 A1 EA200600648 A1 EA 200600648A1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
radical
purin
derivatives
hiv replication
Prior art date
Application number
EA200600648A
Other languages
English (en)
Other versions
EA009734B1 (ru
Inventor
Поль Адриан Ян Жанссен
Паулус Йоаннес Леви
Марк Рене Де Жонж
Люсьен Мария Хенрикус Койманс
Фредерик Франс Дезире Дайер
Ян Херес
Хендрик Мартен Винкерс
Рубен Герардус Жорж Лендерс
Дирк Альфонс Лео Ванденпют
Original Assignee
Янссен Фармацевтика Н. В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н. В. filed Critical Янссен Фармацевтика Н. В.
Publication of EA200600648A1 publication Critical patent/EA200600648A1/ru
Publication of EA009734B1 publication Critical patent/EA009734B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение относится к применению соединения формулы (I) для производства лекарственного средства для профилактики или лечения инфекции ВИЧ, где соединением формулы (I) является соединение формулы (I), его N-оксид, фармацевтически приемлемая аддитивная соль, четвертичный амин или стереохимически изомерная форма, где А и В, каждый, представляют радикал формулы (а) или (b) и где -C-D-представляет двухвалентный радикал формулы -N=CH-NR- (с-1) или -NR-CH=N- (c-2), при условии что, когда А представляет радикал формулы (а), тогда В представляет радикал формулы (b), и когда А представляет радикал формулы (b), тогда В представляет радикал формулы (а).
EA200600648A 2003-09-25 2004-09-21 Производные пурина, ингибирующие репликацию вич EA009734B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0350659 2003-09-25
PCT/EP2004/052262 WO2005028479A2 (en) 2003-09-25 2004-09-21 Hiv replication inhibiting purine derivatives

Publications (2)

Publication Number Publication Date
EA200600648A1 true EA200600648A1 (ru) 2006-08-25
EA009734B1 EA009734B1 (ru) 2008-02-28

Family

ID=34354400

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600648A EA009734B1 (ru) 2003-09-25 2004-09-21 Производные пурина, ингибирующие репликацию вич

Country Status (19)

Country Link
US (1) US8026245B2 (ru)
EP (1) EP1668011B1 (ru)
JP (1) JP5506751B2 (ru)
KR (1) KR20060121878A (ru)
CN (1) CN100475815C (ru)
AP (1) AP2006003517A0 (ru)
AT (1) ATE500254T1 (ru)
AU (1) AU2004274185B2 (ru)
BR (1) BRPI0414791A (ru)
CA (1) CA2535313C (ru)
DE (1) DE602004031641D1 (ru)
EA (1) EA009734B1 (ru)
ES (1) ES2361835T3 (ru)
IL (1) IL174467A0 (ru)
MX (1) MXPA06002069A (ru)
NO (1) NO20061788L (ru)
TW (1) TW200518758A (ru)
WO (1) WO2005028479A2 (ru)
ZA (1) ZA200602440B (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
RS51752B (sr) 2002-07-29 2011-12-31 Rigel Pharmaceuticals Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina
HRP20130602T1 (en) 2003-07-30 2013-07-31 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
JP2007526339A (ja) * 2004-03-02 2007-09-13 ニューロジェン・コーポレーション アリール置換プリン類縁体
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
EP2402011B1 (en) 2004-08-25 2012-11-14 Ardea Biosciences, Inc. S-triazolyl alpha-mercaptoacetanilides as inhibitors of HIV reverse transcriptase
JP4958785B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CA2602257A1 (en) 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as hsp90-inhibitors
WO2006122003A2 (en) * 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
WO2006136005A1 (en) * 2005-05-16 2006-12-28 Prometic Biosciences Inc. Purine derivatives and their use for treatment of autoimmune diseases
WO2007130075A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CA2608367C (en) 2005-06-08 2014-08-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
CA2668997C (en) 2006-11-09 2012-10-09 Ardea Biosciences, Inc. 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
EA201270666A1 (ru) 2007-11-27 2012-12-28 Ардеа Биосайнсиз Инк. Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EP2220091B1 (en) 2007-12-14 2012-07-25 Ardea Biosciences, Inc. Reverse transcriptase inhibitors
WO2010011768A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011000839A (es) 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolpiridina cinasa.
AU2009279611A1 (en) 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
MX2011011653A (es) 2009-05-06 2012-01-20 Vertex Pharma Pirazolopiridinas.
KR101447789B1 (ko) 2009-11-12 2014-10-06 에프. 호프만-라 로슈 아게 Ｎ-7 치환된 퓨린 및 피라졸로피리미딘 화합물, 조성물 및 사용 방법
AU2011209651A1 (en) 2010-01-27 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
EP2550272A1 (en) 2010-01-27 2013-01-30 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
EP2528917B1 (en) 2010-01-27 2016-10-19 Vertex Pharmaceuticals Incorporated Pyrazolopyridines useful for the treatment of autoimmune, inflammatory or (hyper)proliferative diseases
EP2536696A1 (en) 2010-02-18 2012-12-26 Concert Pharmaceuticals Inc. Pyrimidine derivatives
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2962438B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'indolizines, procedes de preparation et application en therapeutique
CN103570688B (zh) * 2012-07-19 2016-06-08 中国科学院上海药物研究所 2，5-二氨甲基吡嗪类化合物、其药物组合物、制备方法和用途
EP3099672A4 (en) 2014-01-31 2017-09-20 ONO Pharmaceutical Co., Ltd. Fused imidazole compounds
CA2971558C (en) 2014-12-18 2023-03-07 Nissan Chemical Industries, Ltd. Ketone or oxime compound, and herbicide
EP3528816A4 (en) * 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
US20210380540A1 (en) * 2018-10-25 2021-12-09 Minakem Process for the preparation of rilpivirine
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
CN114805369B (zh) * 2022-05-30 2023-05-16 自贡市第四人民医院(自贡市急救中心) 一种2，6-二取代嘌呤类化合物及制备方法及应用
WO2025143856A1 (ko) * 2023-12-27 2025-07-03 주식회사 에이조스바이오 신규 퓨린계 화합물 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
CN1198655C (zh) 1995-11-23 2005-04-27 詹森药业有限公司 通过熔体挤出法制备的环糊精固体混合物
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
HU230522B1 (hu) 1998-03-27 2016-10-28 Janssen Pharmaceutica N.V HIV-gátló pirimidinszármazékok
HU227453B1 (en) 1998-11-10 2011-06-28 Janssen Pharmaceutica Nv Hiv replication inhibiting pyrimidines, and pharmaceutical compositions containing them
WO2000037471A1 (en) * 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
WO2001049688A1 (en) 2000-01-07 2001-07-12 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6897307B2 (en) * 2002-03-28 2005-05-24 Novartis Ag Process for preparing 2,6-diaminopurine derivatives
SG145748A1 (en) * 2003-08-15 2008-09-29 Irm Llc 6-substituted anilino purines as rtk inhibitors
WO2006122003A2 (en) * 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv

Also Published As

Publication number Publication date
BRPI0414791A (pt) 2006-11-21
AU2004274185A1 (en) 2005-03-31
ZA200602440B (en) 2007-09-26
JP2012006945A (ja) 2012-01-12
EP1668011A2 (en) 2006-06-14
EA009734B1 (ru) 2008-02-28
JP4825672B2 (ja) 2011-11-30
IL174467A0 (en) 2006-08-01
CA2535313C (en) 2012-07-17
WO2005028479A3 (en) 2005-06-16
DE602004031641D1 (de) 2011-04-14
JP5506751B2 (ja) 2014-05-28
AP2006003517A0 (en) 2006-02-28
MXPA06002069A (es) 2006-05-19
AU2004274185B2 (en) 2009-12-10
CN1856496A (zh) 2006-11-01
CA2535313A1 (en) 2005-03-31
ATE500254T1 (de) 2011-03-15
KR20060121878A (ko) 2006-11-29
EP1668011B1 (en) 2011-03-02
NO20061788L (no) 2006-04-24
TW200518758A (en) 2005-06-16
ES2361835T3 (es) 2011-06-22
JP2007506707A (ja) 2007-03-22
US20060293330A1 (en) 2006-12-28
WO2005028479A2 (en) 2005-03-31
US8026245B2 (en) 2011-09-27
CN100475815C (zh) 2009-04-08

Similar Documents

Publication Publication Date Title
EA200600648A1 (ru) Производные пурина, ингибирующие репликацию вич
SA521430792B1 (ar) مركبات مضادة للفيروسات محتوية على نيتريل
SA522432955B1 (ar) Kras g12c مثبطات
NO2020026I1 (no) Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet
GEAP202416435A (en) Anti-viral compounds
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
GB0612423D0 (en) Therapeutic agents
EA200501327A1 (ru) Пиримидины и триазины, ингибирующие вич репликацию
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA200600973A1 (ru) ПИРИДО[2,3-d] ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2
EA200970047A1 (ru) Водные суспензии тмс278
EA200600892A1 (ru) Новые хинолиновые производные
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
GB0413087D0 (en) Therapeutic compounds
EA200601654A1 (ru) Ингибиторы интегразы вич
CA3156303A1 (en) 5-fluoronicotinamide derivatives and uses thereof
UY27577A1 (es) Inhibidores de la integrasa del vih
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
MX2022012881A (es) Inhibidores de replicacion del virus de inmunodeficiencia humana.
JOP20220038A1 (ar) عوامل مضادة للملاريا
EA200901599A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
NO20030297L (no) Aryl sulfonamider som serotoninantagonist for behandling av fedme
CL2024001073A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
EA202192234A1 (ru) Комбинированная терапия для применения в лечении рака

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM